1 January 2024 in Cancer Control
Background: Alterations in PI3K function are directly related to cancer, making PI3K inhibitors suitable options for anticancer therapies. Information on therapy using different types of PI3K inhibitors is available in literature, providing indications of trends in developing new therapies. Although some studies on PI3K inhibitors for cancer treatment provide clinical evidence, they do not allow a careful search for potential PI3K inhibitors conducted by development indicators. Here, we performed a foresight study of clinical trials involving PI3K inhibitors from the past 11 years using indicators of clinical evolution to identify technological trends and provide data for supporting recommendations for new study designs. Methods: A comprehensive foresight study was designed based on documents from clinical trials on PI3K inhibitors to perform a systematic and comparative analysis, in order to identify technological trends on new cancer therapies. Results: Our results demonstrate that total number of clinical trials has decreased over the years and, currently, there is a clear prevalence of studies using isoform-specific inhibitors in combined interventions. Clinical trials in Phases I and II were the most frequently found in the database, whereas Phase III trials correspond to 7% of studies. The measurement of clinical trials progression using indicators (drugs in Phase III profile, top-10 drugs, and top-10 combined drugs) demonstrated that the 3 new medicines BKM120, IBI-376, and PF-05212384 have a high potential to provide more efficient cancer treatment in combined interventions. These data also include the groups of targets for each drug, providing a useful and reliable source for design new combinations to overcome the resistance and the poor tolerability observed in some PI3K therapies. Conclusions: The establishment of development indicators based on clinical trials for cancer treatment was useful to highlight the clinical investment in 3 new PI3K drugs and the advantages of combine therapy using FDA-approved drugs.
1 January 2022 in Transinformação
As part of the innovation process, clinical research generates valuable data to assess technological solutions in healthcare, linking scientific research and knowledge transfer to provide beneficial innovations for society. However, the generated clinical data do not appear to be adequately available to the scientific community and society. The present study seeks to analyze the effectiveness of databases of clinical records as a source of relevant information for scientific research. We conducted a comparative analysis of 27 correlations of clinical trials between three different technologies and their scientific articles by consulting two information sources. Making connections between the data from these sources proved to be challenging. In addition, a considerable time lag (40 months on average) was observed between the end of the study and the publication of the results. Among the completed studies, 56% had not published their results in any of the channels studied. In addition to the paucity of reported results, the poor publication record of clinical trials is further evident in the lack of information on these studies in scientific publications. Thus, databases of clinical records are a potential source of information and may come to represent a central tool in the search for new technological solutions in healthcare.
1 January 2022 in Cadernos de Prospecção
O presente trabalho realizou uma prospecção tecnológica a partir de patentes para identificação de derivados das plantas medicinais para o tratamento da tuberculose. O uso de patentes como fonte de informação pode otimizar o desenvolvimento de novos medicamentos para o tratamento da tuberculose. A identificação de novas tecnologias foi realizada pelo portal Orbit Intelligence, utilizando a sentença “(+tuberculos+)/TI/AB AND (A61K OR A61P)/IPC AND PRD >= 2015” como estratégia de pesquisa. Foram identificadas 16 famílias de patentes apresentando derivados de plantas medicinais com evidência de eficácia in vitro contra cepas resistentes de Mycobacterium tuberculosis. A proteção patentária dos produtos naturais identificados está restrita aos países dos detentores dos novos produtos: China, República da Coreia e Rússia. A maior parte dos derivados de plantas medicinais identificados são substâncias isoladas, principalmente flavonoides e terpenos, extraídos de diferentes espécies de plantas, caracterizando-se, dessa forma como, fitofármacos.
1 October 2020 in Journal of Intellectual Property Law and Practice
According to Myers and others, 1 44 per cent of all vascular plants and 35 per cent of all species of the four vertebrate groups are confined to only 25 biodiversity hotspots, which comprise only 1.4 per cent of the Earth’s surface. Among the 25 hotspots surveyed, the vast majority is located in the territories of least developed or developing countries, where the biodiversity is not converted into economic richness. Biological resources have been used as models for the generation of solutions to various challenges faced by our society in the recent past and the acquired knowledge about natural products and processes has proven to be a generator of income. However, the countries and populations which are the real owners of those natural assets and knowledge often do not have their rights recognized and are not included in the value chains created around these natural resources. Consequently, the use of genetic resources (GRs) and associated traditional knowledge (TK) extracted from countries rich in biodiversity has been a source of dissatisfaction. 2 The absence of appropriate authorization from the real custodians, low-income countries and their traditional populations, as well as the lack of recognition and retribution for the use of these resources by researchers around the world are common sources to the discontentment.